Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after market close. Here’s what to look for. Globus Medical beat analysts’ revenue expectations ...

Globus Medical, Inc. (NYSE:GMED) just released its latest quarterly report and things are not looking great. It wasn't a great result overall - while revenue fell marginally short of analyst ...

Globus Medical (NYSE:GMED) announced that its board of directors authorized a share repurchase program totaling up to $500 million.

From new partnerships and launches, here are six developments from Globus Medical so far in 2025. 1. OsteoCentric Technologies entered into a non-exclusive licensing agreement with Globus Medical.

Globus Medical reported its financial results for Q1 2025, revealing a miss on both earnings and revenue forecasts. The company posted an earnings per share (EPS) of $0.68, falling short of the ...

AUDUBON, Pa. (AP) — AUDUBON, Pa. (AP) — Globus Medical Inc. (GMED) on Thursday reported first-quarter earnings of $75.5 million. On a per-share basis, the Audubon, Pennsylvania-based company ...

Across the recent three months, 6 analysts have shared their insights on Globus Medical GMED, expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...